Patient & Visitor InformationContact Us
  • GI Protocols

  • Anal

    1. BrUOG 276: A Phase I/II Evaluation of ADXS11-001, Mitomycin, 5-fluorouracil (5-FU) and IMRT for Anal Cancer
      PI:Howard Safran, MD
      Sites: Rhode Island Hospital, The Miriam Hospital
      Learn more about this study

    Cholangiocarcinoma

    1. LS-P-JSBA: A Phase I Study of LY2801653 in Patients with Advanced Cancer
      PI: Kimberly Perez, MD
      Sites: Rhode Island Hospital, The Miriam Hospital
      Learn more about this study

    Colorectal

    1. BrUOG CR-261: Single Agent Adjuvant Aflibercept (ziv-Aflibercept) for Patients with Resected or Ablated Metastatic Colorectal Cancer: A Randomized Phase II Study
      PI: Howard Safran, MD
      Sites: Rhode Island Hospital, The Miriam Hospital
      Learn more about this study

    Esophageal

    1. RTOG 1010: A Phase III Trial Evaluating the Addition of Trastuzumab to Trimodality Treatment of HER2-Overexpressing Esophageal Adenocarcinoma
      PI: Howard Safran, MD
      Sites: Rhode Island Hospital, The Miriam Hospital
      Learn more about this study

    Gastric

    1. LS-P-POST: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0010718CI in subjects with metastatic or locally advanced solid tumors and expansion to selected indications
      PI: Howard Safran, MD
      Sites: Rhode Island Hospital, The Miriam Hospital
      Learn more about this study

    Pancreatic

    1. BrUOG P-278: FOLFOX-A For Pancreatic Cancer: A Brown University Oncology Research Group Study
      PI: Howard Safran, MD
      Sites: Rhode Island Hospital, The Miriam Hospital
      Learn more about this study

    2. BrUOG P-295: A Phase II Adjuvant FOLFOX-A For Resected Pancreatic Cancer Study
      PI: Howard Safran, MD
      Sites: Rhode Island Hospital, The Miriam Hospital
      Learn more about this study